Emerging from Verséa Health and Backed by Industry Veterans, DefEYE, Inc. sets
its sights on enhancing clinical and surgical care across ocular conditions
SARASOTA, FL., October 1, 2025 — DefEYE Inc. (DefEYE), a privately held ophthalmic biologics
company with a portfolio of decellularized biologic solutions, today announced its launch as an
independent company, effective October 1, 2025. The company previously operated as Verséa
Ophthalmics, Inc., a subsidiary under the Verséa Health, Inc. holdings company.
DefEYE will be led by a seasoned leadership team with deep expertise in ophthalmic therapeutics,
diagnostics, and commercialization. Rob Sambursky, MD, a Wills Eye trained corneal specialist
and proven serial entrepreneur with a track record of leading companies across both diagnostic
and therapeutic platforms, has been appointed Chief Executive Officer. He will be joined by
Robert Glashow, an accomplished finance and operations executive with extensive experience
guiding initial public offerings, mergers, and acquisitions, who will serve as Chief Financial Officer.
“We are extremely excited about the official launch of DefEYE, Inc. and look forward to building
upon the productive partnerships we have already established with both ophthalmologists and
optometrists nationwide,” said Rob Sambursky, MD, Chief Executive Officer of DefEYE.
“Leveraging our highly differentiated and innovative product portfolio, our experienced eye care
team is prepared to educate, train, and support eye care professionals and their patients
suffering from ocular surface diseases as well as recovering after ocular surgery.”
In addition, Rahim Hirji, RPh, will serve as Senior Vice President of Marketing and brings broad
commercial experience, including marketing, market access, professional relations, and
successful product launches. Tyler Johnson, VP of Market Development and Rebecca Chandler
VP of Strategic Accounts will round out the commercial leadership team.
DefEYE secured exclusive commercial rights to a portfolio of decellularized biologics, including
the BIOVANCE franchise of products which includes BIOVANCE 3L Ocular and BIOVANCE amniotic
decellularized basement membrane products. Additionally, DefEYE has access to commercial
rights to additional decellularized human placenta-derived biologics with strong potential
applications in eye care.
Be sure to visit DefEYE at upcoming eye care congresses to learn more including the American
Academy of Optometry meeting in Boston at booth #710 from October 8 – 11, 2025 as well as
the American Academy of Ophthalmology meeting in Orlando at booth #3205 from October 18 – 20, 2025.
BIOVANCE® Product Portfolio:
BIOVANCE and BIOVANCE 3L Ocular are the only decellularized basement membranes used to
elevate the management of ocular surface disease and ocular surgery. BIOVANCE 3L Ocular has
a tri-layer architecture containing a preserved natural epithelial basement membrane and intact
extracellular matrix structure. As a barrier membrane, BIOVANCE 3L Ocular is intended to protect
the underlying tissue and preserve tissue plane boundaries. Applications include corneal and
conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix
and reconstruction.
About DefEYE, Inc.
DefEYE, Inc. is a rapidly growing ocular company on a mission to transform and personalize
therapeutic approaches in eye care. The company focuses on delivering a portfolio of innovative
decellularized biologic solutions that optimize treatment and management of various eye care
conditions, including ocular surface diseases, pterygium surgery, and other surgical
interventions. To learn more, visit www.defeye.com.
Media Contact
Amy Phillips
Amy.Phillips@launchlabpartners.com
412.327.9499
